Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Stocks fell on Wall Street Tuesday, pulled down by losses in the same big tech companies that have been the main drivers of the market’s rally so far this year. The downturn pulled every major index ...

Yacktman Asset Management's Q3 2025 13F portfolio value declined to $7.26B, with 70 holdings and ~9% cash. Learn more about ...

Fintel reports that on November 4, 2025, Morgan Stanley maintained coverage of Kimberly-Clark (NasdaqGS:KMB) with a ...

Beta Technologies' public market debut is a capstone to founder and CEO Kyle Clark's untraditional approach to building an aviation company.

The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.

Stocks fell on Wall Street, pulled down by losses in the same big tech companies that have been the main drivers of the ...

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Evercore also said Kimberly’s move expands its footprint into two stable, cash-generative global categories, personal hygiene and consumer health, that have high barriers to entry and rational pricing ...

Gift Nifty was trading around 25,869 level, a discount of nearly 30 points from the Nifty futures’ previous close, indicating a negative start for the Indian stock market indices.